Last update: February 2022
Throughout the ongoing pandemic, we have joined forces to fight COVID-19 in every way possible. This includes developing vaccines at large scales to help prevent and control COVID-19.
"Despite multiple vaccines becoming available, there remain vast global health needs further exasperated by the unpredictability of virus variants. Sanofi is continuing to complement its expertise and resources with that of our peers to help prevent and control the pandemic over the long term."
Paul Hudson
CEO Sanofi
For over a century, vaccines have been a pillar of medical care. Every vaccine developed to date is based upon the same fundamental principle: by teaching our immune systems to recognize a pathogen and destroy it, we can help protect our bodies from infectious diseases. We are building on this principle to develop vaccines against SARS-CoV-2, the coronavirus that causes COVID-19.
In collaboration with the US BARDA, our vaccine candidate uses our recombinant protein manufacturing platform together with GSK’s pandemic adjuvant platform.
On February 23rd 2022, we announced that we intend to submit data from both our booster and Phase 3 efficacy trials as the basis for regulatory applications for this vaccine.
"All our decisions are and will always be driven by science and data. We remain confident and committed to developing and manufacturing safe and efficacious COVID-19 vaccines."
Thomas Triomphe
Executive Vice President, Vaccines
Supporting global supply
We also keep our commitment to making a strong contribution to current global public health priorities by supporting manufacturing and supply of half a billion doses of three different currently approved vaccines: BioNTech’s approved COVID-19 vaccine, co-developed with Pfizer, the vaccine developed by Johnson & Johnson, and the vaccine developed by Moderna.
We are working across multiple countries and in coordination with partner manufacturing sites to make vaccines at the extremely large scales required by the pandemic. The manufacturing process is a complex, never-ending job, but our aim is to supply vaccines to as many people as possible.
Frequently Asked Questions (FAQ)
R&D Pipeline
Update on our COVID-19 Vaccine Candidate
MAT-GLB-2101933 02/2022 v2.0